Evidence map›Paper›PMID 30782143›Full record

ArticleBMC psychiatry2019

A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder.

Andrea Galova, Patricia Berney, Jules Desmeules, Ioannis Sergentanis, Marie Besson

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Catatonia in older adults: A systematic review.World journal of psychiatry · 2022
    Article
  5. Article
  6. Clozapine discontinuation withdrawal symptoms in schizophrenia.Therapeutic advances in psychopharmacology · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Andrea GalovaPsychopharmacology Unit, Clinical pharmacology and toxicology division, Acute Medicine Department, Geneva University Hospital, Geneva, Switzerland.ORCID 0000-0003-0424-7265
Patricia BerneyPsychopharmacology Unit, Clinical pharmacology and toxicology division, Acute Medicine Department, Geneva University Hospital, Geneva, Switzerland.
Jules DesmeulesClinical pharmacology and toxicology division, Acute Medicice Department, Geneva University Hospital, Geneva, Switzerland.
Ioannis SergentanisLiaison Psychiatry and Crisis Intervention Unit, Psychiatry department, Geneva University Hospital, Geneva, Switzerland.
Marie BessonPsychopharmacology Unit, Clinical pharmacology and toxicology division, Acute Medicine Department, Geneva University Hospital, Geneva, Switzerland. Marie.Besson@hcuge.ch.
University Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRebound cholinergic syndrome is a rare, but well known unwanted phenomenon occurring after abrupt clozapine discontinuation. There have been previous reported cases of cholinergic rebound in the literature; however, these reports described cholinergic rebound following cessation of high doses of clozapine in patients diagnosed with schizophrenia. Here, we report a case of rebound cholinergic syndrome and catatonia in a male patient three days after abrupt discontinuation of 50 mg of clozapine prescribed for type I bipolar affective disorder. CASE PRESENTATION: A 66-year old male of Spanish origin, treated for type I bipolar affective disorder for 15 years and for Crohn disease, was brought to the emergency department because of a sudden onset of mutism, dysphagia and trismus. He was described catatonic and presented hypertension, tachycardia and tachypnea. His body temperature was normal and the laboratory tests were unremarkable at presentation. A head CT and an EEG were in the normal range. While reviewing his history, it appeared the he was on clozapine 50 mg a day, first introduced 2 months ago, during a previous hospitalization for a manic episode resistant to other mood stabilizers. For an unknown reason, the patient's psychiatrist stopped clozapine three days before the admission and replaced it by risperidone 5 mg and quetiapine 200 mg daily. A cholinergic rebound syndrome was then evoked. The patient's ability to speak recovered dramatically and fast after the intravenous administration of 2.5 mg of biperiden supporting the diagnosis. Risperidone and quetiapine were also stopped. The patient fully recovered in 20 days after the reintroduction of 50 mg of clozapine and 2.5 mg of biperiden daily.

conclusionsThis case report underscores that cholinergic rebound syndrome may occur in patients suffering from bipolar affective disorders, being on clozapine as a mood stabilizer. The low dose clozapine does not preclude severe manifestations of the phenomenon. Progressive tapering should therefore be adopted in any case.

Indexed as

Withholding TreatmentAgedAntipsychotic AgentsBipolar DisorderCatatoniaCholinergic AgentsClozapineHumansMaleSubstance Withdrawal SyndromeAntipsychotic AgentsCholinergic AgentsClozapineWithdrawal syndromes-cholinergic rebound syndrome-low dose clozapine -bipolar affective disorder-Pharmacodynamic properties-overlapping switch strategies-case report

Identifiers

PMID30782143
PMCPMC6381751
OpenAlexW2921784834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.